As of June 20, 2025, PharmaResearch Co Ltd (214450.KQ) reports a ROE (Return on Equity) of 17.06%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of PharmaResearch Co Ltd's ROE (Return on Equity)
Over recent years, PharmaResearch Co Ltd's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-12-31 | 17.06% |
| 2023-12-31 | 17.68% |
| 2022-12-31 | 11.81% |
| 2021-12-31 | 15.29% |
| 2020-12-31 | 13.35% |
This slight upward trend highlights how PharmaResearch Co Ltd manages its efficiency in generating profits from shareholders' equity over time.
Comparing PharmaResearch Co Ltd's ROE (Return on Equity) to Peers
To better understand PharmaResearch Co Ltd's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| PharmaResearch Co Ltd (214450.KQ) | 17.06% |
| L&C Bio Co Ltd (290650.KQ) | 49.61% |
| Isu Abxis Co Ltd (086890.KQ) | 14.59% |
| Hans Biomed Corp (042520.KQ) | 13.47% |
| BNC Korea Co Ltd (256840.KQ) | 12.26% |
| Cell Biotech Co Ltd (049960.KQ) | 12.18% |
Compared to its competitors, PharmaResearch Co Ltd's ROE (Return on Equity) is among the highest compared to peers, suggesting efficient use of shareholder equity to generate profits.